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Aims: This retrospective analysis sought to identify markers that might distinguish between acute 
heart failure (HF) and worsening HF in chronic outpatients. 
Methods and Results: The BIOSTAT-CHF index cohort included 2516 patients with new or 
worsening HF symptoms: 1694 enrolled as inpatients (acute HF) and 822 as outpatients 
(worsening HF in chronic outpatients). A validation cohort included 935 inpatients and 803 
outpatients. Multivariable models were developed in the index cohort using clinical 
characteristics, routine laboratory values, and proteomics data to examine which factors predict 
adverse outcomes in both conditions and to determine which factors differ between acute HF and 
worsening HF in chronic outpatients, validated in the validation cohort.  
Patients with acute HF had substantially higher morbidity and mortality (6 months mortality was 
12..3% for acute HF and 4..7% for worsening HF in chronic outpatients). Multivariable models 
predicting 180-day mortality and 180-day HF re-admission differed substantially between acute 
HF and worsening HF in chronic outpatients. CA-125 was the strongest single biomarker to 
distinguish acute HF from worsening HF in chronic outpatients, but only yielded a C-index of 
0..71. A model including multiple biomarkers and clinical variables achieved a high degree of 
discrimination with a C-index of 0..913 in the index cohort and 0..901 in the validation cohort. 
Conclusion: The study identifies different characteristics and predictors of outcome in acute HF 
patients as compared to outpatients with chronic HF developing worsening HF. The markers 








Acute heart failure; acute heart failure diagnosis; acute heart failure treatment. 
Introduction 
Acute heart failure (AHF) is defined as a worsening of symptoms and signs of heart failure (HF) 
requiring urgent care inclusive (but not limited to) intravenous therapy and hospital 
admission.(1) Following a series of neutral studies in which new interventions for AHF were not 
shown in large studies to be associated with improvements in either patients’ symptoms or short- 
and long-term outcomes,(2) some opinion leaders have raised doubt whether AHF is a separate 
condition or just a part of the natural course of chronic heart failure.(3) At the same time doubts 
have been raised that some of the failure in demonstrating positive effects in large AHF studies 
relates to dilution of the patient population;(4) i.e., that patients enrolled in larger confirmatory 
studies may not have “true” AHF but have other disorders, chiefly chronic HF that has slightly 
deteriorated.(4) On the one hand some argue that the decision to admit a patient with AHF is 
subjective and variable and hence HF deterioration managed in the outpatient setting is not a 
different entity than AHF leading to hospital admission, while others argue that those are 
different conditions, the latter having a distinct pathophysiological mechanism – associated with 
inflammatory activation, more congestion, and end organ damage.(5) One of the obstacles in 
resolving these differences, and possibly developing effective therapies for AHF, is that there are 
no objective measures that help determine whether a patient is truly “acute”, i.e., has AHF. All 
objective measures utilized in the diagnosis of AHF to date (natriuretic peptides levels, chest X-
ray or lung ultrasound) can also be found to be affected in patients with stable chronic HF who 
have slight outpatient deterioration.  
In the current analysis we have examined the characteristics of patients enrolled in the 





Failure) study where patients with both AHF requiring hospital admission and worsening of HF 
managed in an outpatient clinic were enrolled and followed.(6) While the absolute risk of 
adverse clinical outcomes overlapped in these two patient groups, the characteristics and 
prognosis of patients enrolled in the inpatient versus the outpatient setting in this study were 
found to differ.(7) The objective of this retrospective analysis was to identify markers that may 
distinguish between AHF and chronic HF patients with outpatient exacerbations and determine 




Index and validation cohorts 
The BIOSTAT-CHF project provided access to data from an index cohort of 2516 heart failure 
patients enrolled between December 2010 and December 2012 in 69 centers in 11 European 
countries. In the Index Cohort adult patients with new or worsening heart failure symptoms, 
objective evidence of cardiac dysfunction, treated with at least 40 mg/day furosemide or 
equivalent, and receiving 50% or less the target doses of evidence-based therapies were enrolled 
in either the inpatient or outpatient setting and patients were followed for a median of 21 
months.(6). For the Validation cohort inclusion criteria were similar, although outpatients could 
have been recruited without worsening of heart failure. Data were available from a validation 
cohort of 1738 patients enrolled in either the inpatient or outpatient setting between October 
2010 and April 2014 in six centers in Scotland, UK. Patients in the validation cohort had a heart 
failure diagnosis and a previous admission with heart failure requiring diuretic therapy, and were 





evidence-based therapies at entry. The study design of BIOSTAT-HF, baseline characteristics of 
the two cohorts and various modeling results have been described previously (6-8).  
 
Patient characteristics and clinical outcomes 
In order to develop a discriminatory model for acute HF and outpatient worsening HF (OP-
WHF) we used reported hospitalization status (inpatient or outpatient) as surrogate. Model 
development was based on basic patient characteristics collected at study entry and baseline (age, 
sex, LVEF, BMI, vital signs, medical history), as well as baseline laboratory test values from 
blood samples analyzed locally or from blood samples that were frozen for shipment to central 
laboratories for analysis:  
1. Local and routine central laboratory: Local laboratory results considered in the models 
included white blood cell count, red blood cell count, platelet count, hemoglobin, urea, 
glomerular filtration rate estimated from local creatinine using the CKD-EPI equation,(9) 
sodium, potassium, total bilirubin, glucose, AST, ALT, GGT, ALP, HDL, LDL, and 
triglycerides.  NT-proBNP, high-sensitivity troponin T (hsTnT), and GDF-15 were 
centrally measured using a Roche Elecsys® cobas analyzer (Roche Diagnostics, 
Mannheim, Germany); aldosterone, renin, FGF23, urea, creatinine, calcium, phosphate, 
albumin, iron, ferritin, transferrin, hepcidin, and sTFR were also measured centrally.  
2. Specialty biomarkers: Three biomarkers (TnI, ET-1, and IL-6) were measured using 
enzyme-linked immunosorbent assays (Singulex Inc.) on a Luminex platform. pro-ENK 
and bio-ADM were measured on a Sphingotec platform (Spingotec GmbH). CA125 was 
measured using a chemiluminescent microparticle immunoassay on an ARCHITECTi 





3. Proteinomics/Olink panels: The BIOSTAT-CHF project included a comprehensive 
proteomic database measured by the Olink Proseek analysis service (Olink Proteomics, 
Uppsala, Sweden). The Olink platform utilizes a high-throughput multiplex immunoassay 
based on a proprietary Proximity Extension Assay (PEA) technology, where each 
biomarker is addressed by a matched pair of antibodies, coupled to unique, partially 
complementary oligonucleotides, and measured by quantitative real-time polymerase 
chain reaction (PCR). Results are expressed in the form of relative quantification 
(Normalized Protein eXpression or NPX) which are logarithmically related to protein 
concentration but cannot be converted to absolute protein concentrations. The BIOSTAT-
CHF database comprised data from four Olink panels: Cardiovascular II, Cardiovascular 
III, Immune Response, and Oncology II, providing baseline measurements for a total of 
368 proteins for most patients of both cohorts. Proteins can be recognized by a UniProt 
identifier.(10) For model development, we excluded 4 biomarkers from analysis as the 
same proteins were measured on more than 1 panel (1 copy each of AREG and SCF, and 
two copies of IL-6), leaving a total of 364 unique proteins for analysis.  
In a preliminary step, we excluded baseline parameters with mostly missing observations in the 
index cohort and selected representative parameters in case of highly correlated or collinear 
variables. Olink measures were nearly perfectly correlated with other central measures of the 
same parameter. When both were available models were developed considering only the Olink 
parameter; for example, only MUC16 and not CA125 was considered in multivariable Model 3 
for distinguishing AHF from OP-WHF. A differential expression analyses of the Olink proteins 
was performed using the Linear Models for Microarray data analysis (Limma) software (version 





if the absolute value of the fold change exceeded 1.24 (|log2 FC|>0.31), the p-value for the t-test 
that the log2FC differs from zero and the false discovery rate (FDR) <0.05. A volcano plot [a plot 
of -log10(p-value) versus log2 fold change] was used to visualize the differential expression of 
these markers in patients enrolled in the inpatient versus the outpatient setting. Clinical endpoints 
considered for analysis were the two components of the primary endpoint of BIOSTAT-CHF: 
all-cause death and first re-admission for heart failure. For the development of prognostic 
models, the time to the first occurrence of each clinical endpoint was evaluated through 180 days 
after baseline. Partially missing re-admission or death dates were imputed with the 15th of the 
month if only day was missing, or July 1st if both day and month were missing. Re-admission 
dates before and up to (≤) the respective baseline visit dates were excluded from analysis. Time 
to event was computed for all patients with a recorded event. Time to event for patients without a 
recorded event was censored at the earlier of 180 days after baseline or the individual end of 
study date. For the analysis of time to first occurrence of HF re-admission, time was censored at 
date of death for subjects who were not re-admitted for HF as the primary cause.  
 
Statistical model development 
Hospitalization status (inpatient versus outpatient) was analyzed using logistic regression. Time 
to all-cause death through 180 days and time to first HF re-admission through 180 days were 
analyzed using Cox proportional hazards models. We examined a number of classification 
methods in addition to logistic and Cox regression including Boosted Logistic Regression 
(LogitBoost), linear discriminant analysis with stepwise feature selection (stepLDA), neural 
networks (nnet), k-nearest neighbors (knn), CART (rpart), C5.0, and random forest (rf) 





forest appeared best, with generally the highest area under the receiver operator characteristic 
curves (AUCs) and highest scaled Brier scores (which can be interpreted as correlation 
coefficients). Thus, pre-selection of Olink candidate predictors for the logistic regression models 
was based on the average variable importance rank for these two methods. We used the set of 
index cohort patients with complete Olink data as a training set for building classifiers that 
would predict inpatient status. Variable importance for each Olink marker was calculated by 
independently using C5.0(12) as well as Random Forests(13) as classification methods in a 
repeated 5-fold cross-validation approach using R package “caret”(14). Variable importance 
measures within each method were ranked using sports ranking; markers were then sorted by 
their average rank across the two methods. The top 50 Olink markers were selected as candidates 
for the inpatient status model (Supplementary Table 6), and the top 20 markers as candidates for 
the outcome models except for the top 10 in the case of outpatient mortality.    
The full set of candidate predictors for each of the five models is given in Supplementary Table 
11. For discriminating between in- and outpatients, in Model 1 we considered only patient 
characteristics, vital signs and locally- and centrally-measured laboratory values; we additionally 
considered medical history for prognostic models. For model 2, we further considered specialty 
biomarker measures; for model 3, we added the pre-selected Olink proteins. Missing values in 
the final analysis data set were imputed using a multi-chain Monte Carlo approach (R package 
“mice”(15)) and 10 imputed data sets were generated for the index cohort.  
For each model, each continuous candidate baseline variable was first tested for non-linearity of 
its association with the model outcome by assessing the significance of the non-linear 
components of a restricted cubic spline transformation applied to the baseline variable in the 





association was deemed significantly non-linear and this behavior was observed consistently 
across the 10 imputed data sets of the index cohort, appropriate non-linear transformations were 
selected from a set of pre-specified transformations (such as quadratic, cubic, or linear spline 
transformations). Selection was based on values of Akaike’s Information Criterion and visual 
inspection of plotting the predicted outcome against the baseline values. Baseline variables with 
highly skewed distributions were log2 transformed for analysis. Logistic or Cox regression with 
backwards selection was run on the 10 imputed data sets computing pooled p-values according to 
Rubin’s algorithm(16) in each selection step and with the p-value criterion of 0.01 for staying in 
the inpatient models, and 0.05 for staying in the prognostic models. Estimated effect sizes, their 
95% confidence intervals and p-values were pooled using Rubin’s algorithm.  
As a measure of discriminatory ability, the C-index pooled across the 10 imputed data sets was 
computed for each model. We further derived “final” models by combining the regression 
coefficients using Rubin’s algorithm, applied each final model on the imputed data sets and 
derived the C-index for the final models as the average C-index across the imputed data sets. For 
internal validation, bootstrap samples of the imputed data sets of the index cohort were drawn, 
each time using the same random sample of patients for all imputations. Backwards selection and 
model fitting were repeated for each bootstrap sample in order to estimate bias-corrected C-
indices and confidence intervals for each multivariable model. For external validation, the final 
models were applied to the imputed data sets of the validation cohort and pooled C-indices 
estimated. We further examined discrimination and calibration of our models through receiver-
operator characteristics (ROC) curves and calibration plots. 
The model for inpatient versus outpatient status was externally validated in the validation cohort. 





reported in the validation cohort and were thus multiply imputed. We successively added a small 
random sample of validation patients (n=11) to each of the 10 imputed data sets of the index 
cohort. We then imputed missing data for each subset of 11 validation patients in each imputed 
data set, repeated this step 158 times, thus generating 10 imputed data sets for the 1738 subjects 
in the validation cohort as well.  
To further explore differences in prognostic factors between inpatients and outpatients, we 
applied the final multivariable models in inpatients to the outpatients. For HF readmission, all 
variables in the final model were used, while for death due to the limited number of events in 
outpatients the top 8 predictors were chosen. We further compared the fit of the final inpatient 
and outpatient models in the inpatients using partial likelihood ratio tests(17) as implemented in 
R package nonnestcox; for each clinical endpoint, the two final models were fitted within the 
inpatients and separately for 10 imputed data sets. 
SAS® version 9.4 (SAS Institute, Cary, NC, USA) and R version 3.5.1(18) software was used 
for all analyses. 
 
Data availability 
The data that support the findings of this study are available from University Medical Center 
Groningen but restrictions apply to the availability of these data, which were used under license 
for the current study, and so are not publicly available. Data are however available from the 
authors upon reasonable request and with permission of University Medical Center Groningen. 
 
Results 





Summary statistics for selected baseline characteristics are presented in Table 1 by cohort and 
patient status. A volcano plot showing the differential expression of the Olink panel proteins in 
inpatients versus outpatients is presented in Figure 1.  Mucin-16 (MUC16), also known as 
CA125, appears to be the most differentially expressed, when considered without simultaneous 
adjustment for other proteins (i.e., univariably). In BIOSTAT-CHF, a doubling of CA125 
(ARCHITECTi) as a continuous measure increased the odds of being an inpatient by 50% (OR 
1.50, 95% CI 1.42-1.58, p<0.0001) with an AUC of 0.6983 (Table 2); results for MUC-16 
measured on the Olink platform were similar (OR 1.58, 95% CI 1.48-1.69, p<0.0001). MUC-16 
was selected for inclusion in the multivariable model (Table 3) with a somewhat smaller 
association with inpatient status (OR 1.30, 95% CI 1.17-1.46). At a threshold of 100 U/mL,(19) 
CA125 (ARCHITECTi) greater than the threshold had an AUC of 0.6278, sensitivity of 0.3832, 
specificity 0.8725, positive predictive value (PPV) 0.8610 and negative PV (NPV) 0.4070. ....... 
We also examined the ability of the traditional marker of HF severity – NT-proBNP – to 
discriminate between inpatients and outpatients. A doubling of NT-proBNP (cobas) was 
associated with an OR of 1.32 (95% CI 1.25-1.39, p<0.0001) for inpatient status with an AUC of 
0.6395. Using a cut-point of 400 pg/mL(20)  resulted in an AUC of 0.5421, sensitivity 0.9400, 
specificity 0.1442, PPV 0.6936, and NPV 0.5384. Thus, the traditional cut-point displayed high 
sensitivity and very low specificity. Note that when adjusted simultaneously for other proteins 
(Table 3), patients with a higher NT-proBNP were less likely to be an in-patient (OR 0·87 per 1-
log increase, 95% CI 0·78-0·96).  
We examined the ability of other biomarkers identified as potential markers of acutely ill heart 





individually was unable to discriminate between inpatients and outpatients, with AUCs of about 
0.500 signifying an ability no better than chance to predict the status. 
Table 3 presents the selected multivariable logistic regression models for inpatient versus 
outpatient; Supplementary Figures 1 and 2 show in the index and validation cohorts the receiver-
operator-characteristic (ROC) and calibration curves, respectively. The discrimination of the 
final multivariable model 3, which included 21 of the 50 Olink proteins considered, was 
excellent, with a c-index (AUC) of 0.9133 in the index cohort and of 0.9011 in the validation 
cohort. The performance characteristics of this model – including AUC and scaled Brier score – 
were better than those using classification methods (Supplementary Table 1). 
 
Death through Day 180 
In the Index cohort a total of 208 (12.3%) patients enrolled in the inpatient setting, and 39 (4.7%) 
patients enrolled in the outpatient setting, died by day 180. In the validation cohort 162 (17.3%) 
of the patients enrolled in the inpatient setting died at 6 months versus 25 (3.1%) in the 
outpatient setting. Final multivariable prognostic models are presented in Tables 4 and 5 for 
inpatients and outpatients, respectively. The full models (Model 3) had good discrimination with 
c-indexes of 0.8281 and 0.8460, respectively. Although difficult to compare directly because the 
paucity of events among outpatients restricted the number of candidate predictors that could be 
considered for that outcome, the prognostic factors differed for the two patient groups. When 
only considering patient characteristics and local and central laboratory data (Model 1), for 
example, FGF23, NT-proBNP, renin, and troponin T were all highly prognostic in inpatients, 





The 8 most prognostic factors from the inpatient multivariable Model 3 for death provided much 
less discrimination in outpatients with a c-index 0.7464 (Supplementary table 12). And the 
inpatient and outpatient models were found to be distinguishable, and the fit of the inpatient 
model significantly better than the outpatient model, in inpatients. 
 
Heart failure hospitalization through Day 180 
In the Index Cohort, a total of 254 (15.0%) patients enrolled as inpatients, and 73 (8.9%) patients 
enrolled as outpatients, were hospitalized for heart failure by day 180. In the Validation Cohort, 
6-month HF admission was observed in 166 (17.8%) inpatients and 57 (7.1%) outpatients. Final 
multivariable prognostic models are presented in Tables 6 and 7 for inpatients and outpatients, 
respectively. Model discrimination was modest in inpatients, with a c-index of 0.7322 for the full 
model (Model 3); the model including only patient characteristics and local or central laboratory 
data (Model 1) and the model additionally considering specialty laboratory parameters (Model 2) 
had similar discrimination with a c-index of 0.7395 for both. Discrimination for the models in 
outpatients was better, with c-indexes of 0.7966, 0.7984, and 0.8234 for Models 1, 2, and 3, 
respectively. NT-proBNP was a strong prognostic factor in both inpatients and outpatients.  
The inpatient Model 3 applied to outpatients provided less discrimination than the model 
developed in the outpatients, with a c-index of 0.8055 (Supplementary table 13). And the 
inpatient and outpatient models were found to be distinguishable, and the fit of the inpatient 
model significantly better than the outpatient model, in inpatients. 
 
Discussion  
AHF research has been limited in the last decades by three major issues. The first is the lack of 





symptoms and signs requiring urgent care) which has been an impediment to distinguishing 
between patients with “true” AHF versus those with out-patient HF exacerbations not requiring 
urgent care. This had led to significant problems in enrolling AHF patients in large studies.(4) 
Second, related to the lack of ability to define AHF we also know little of its pathophysiology. 
And third, as a consequence of our lack of ability to define AHF and our lack of knowledge of its 
pathophysiology the treatment targets for AHF are also not defined. In the last two decades, most 
therapies developed for AHF were either vasodilators or diuretics – which have both failed to 
show substantial benefit beyond some improvement in very short-term symptoms. 
In the current analysis, AHF and OP-WHF were found to differ in three major domains. First, 
patients with AHF had much higher morbidity and mortality rates. The 180-day mortality and 
HF readmission rates were 12.3% and 15% for the AHF cohort and 4.7% and 8.9% for the OP-
WHF cohort, respectively. Second, prognostic models for adverse outcomes differ for patients 
with AHF versus outpatient exacerbation of HF and models that predict adverse outcomes in 
AHF do not predict well adverse outcomes in outpatient exacerbations of HF. Third and lastly, 
the characteristics and prognosis of patients enrolled in the inpatient versus the outpatient setting 
in this study were found to differ.(7) The current analysis suggests that patients admitted for 
AHF have a different biomarker profile from patients with HF exacerbation not requiring 
admission.  
These findings suggest that different pathophysiological mechanisms leading to different patterns 
of activation of neurohormonal and inflammatory protein markers may be involved in AHF and 
differ from those in out-patient exacerbations of heart failure. If confirmed, these may enable 
development of new diagnostic platforms that would lead to better ability to diagnose patients 





elucidated in further prospective studies. In line with this limitation, as seen above, none of the 
currently proposed biomarkers (natriuretic peptides, CA125, ST2 or troponin) by itself can 
differentiate between AHF and outpatient exacerbation to the degree that the full model can. 
However, more data are required to better elucidate which variables and biomarkers would best 
discriminate the different disorders. As described in the current manuscript the models provided 
may help illuminate new paths in developing better models, but are not in themselves ready to be 
applied immediately in clinical studies.  
In addition, some biomarkers that are differentially activated in AHF or those that seem to be 
associated with adverse outcomes in AHF patients specifically may become targets for 
therapeutic interventions or proxies to therapeutic intervention success enabling more targeted 
therapy for AHF to be developed. Oncological development plans have for the last 20 years been 
successful in targeting specific phenotypes with specific tailored therapies targeting the pathways 
most activated in those phenotypes. Novel approaches assessing in parallel multiple targeted 
interventions in specific phenotypes should be adopted in AHF research. It is possible that the 
lack of success we have encountered in developing new therapies for AHF is not related to the 
proposal that AHF does not exist, but rather to our limited attempts to develop tailored 
phenotype specific treatments.  
 
Study Limitations 
The current analysis is limited by the moderate size of the BIOSTAT study which was designed 
mainly to examine the importance of treatment optimization in patients with worsening HF. 
Some of the outcomes were sparse – especially in the group of patients with exacerbation of HF 





could have been enrolled in the outpatient setting without worsening of HF. Moreover, the 
BIOSTAT study included a cohort of European mostly Caucasian patients mostly with left 
ventricular systolic dysfunction. Therefore, our models need validation in other cohorts of more 
diverse patient populations. The prognostic models developed have relatively low predictive 
value especially when it comes to HF readmissions. Therefore, they cannot be suggested to 
replace currently validated models in acute and chronic HF.  
 
Conclusions 
Our analysis suggests that patients who present with AHF differ from patients who develop HF 
exacerbation not requiring hospital admission. Patients with AHF are characterized by different 
clinical and biomarker profiles, have substantially worse outcomes and different predictors of 
adverse outcomes. The biomarkers that differ between patients with AHF and outpatients with 
HF exacerbation as well as the predictors of adverse outcome in AHF patients can serve to 
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Figure 1 (Central Illustration). Differential protein expression in inpatients relative to 
outpatients 
Presented is a volcano plot of differential protein expression showing the fold change, i.e. the 
ratio of average expression in inpatients to average expression in outpatients, versus the 
corresponding t-test p-value per protein and on logarithmic scales. Higher values on the y-axis 
indicate stronger statistical significance, values >0 on the x-axis indicate upregulation in 
inpatients, and values <0 on the x-axis indicate downregulation in inpatients. Significantly 
differentially expressed proteins have been labeled. 
 
